Despite short-term CMS reimbursement headwinds in wound care, SNWV is gaining market share through expanded distribution. The significant increase in system placements (255 in Q4) suggests future consumables revenue upside. Traders should monitor Q1 2026 revenue execution against guidance and consumables trends. The strong Adjusted EBITDA growth and improved gross margin indicate improving operational efficiency.
Price Chart
Executive Summary
SANUWAVE Health reported record Q4 and full-year 2025 revenues of $13.4M (+29.7% YoY) and $44.1M (+35.0% YoY), driven by strong UltraMist® system and consumables sales. Gross margin declined slightly due to a $486K inventory write-off, but full-year gross margin improved to 77.1%. The company reported GAAP net income of $7.7M in Q4 and $11.8M for the year, though these were heavily influenced by non-cash gains from derivative liabilities. Adjusted EBITDA grew significantly to $4.8M (Q4) and $13.6M (FY). The company issued bullish 2026 guidance, forecasting 16-25% revenue growth to $51.0–55.0M.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $13.4M (+29.7% YoY), record quarter
- Full-year 2025 revenue: $44.1M (+35.0% YoY), record annual revenue
- Q4 gross margin: 74.7% (down from 77.9% YoY) due to $486K PACE inventory write-off; adjusted gross margin was 78.3%
- Full-year 2025 gross margin: 77.1% (up from 75.2% in 2024)
- GAAP operating income: $2.0M (Q4), $4.9M (FY), flat YoY in Q4 despite charges
- Adjusted EBITDA: $4.8M (Q4, +29.7% YoY), $13.6M (FY, +88.9% YoY)
- Net income: $7.7M (Q4) and $11.8M (FY), driven by $5.9M and $8.1M gains from derivative liabilities, respectively
- 255 UltraMist® systems sold in Q4 (vs. 135 in Q4 2024), 624 for full year (vs. 374 in 2024)
- Q1 2026 revenue guidance: $9.6–10.3M (+3–10% YoY), full-year 2026 guidance: $51.0–55.0M (+16–25% vs. 2025)
- Cash balance increased to $11.96M from $10.24M
Financial Impact
Revenue growth accelerating with strong operating leverage; Adjusted EBITDA nearly doubled in 2025. 2026 guidance implies continued strong growth trajectory.
Risk Factors
- GAAP profitability is heavily dependent on non-recurring gains from derivative liabilities
- CMS audit environment and reimbursement cuts may continue to pressure customer volumes in the near term
- Gross margin pressure in Q4 due to product line sunsetting and sales tax expense
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263455 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $4.65 $4.70 | ▼ −1.08% | ▲ +0.13% | $5.07 (−9.03%) |
Aug 6, 2026 11w ago | 8-K | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.07 (+13.78%) |
Aug 6, 2026 11w ago | Press Release | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.07 (+13.78%) |
Jul 30, 2026 12w ago | Press Release | $6.17 $5.88 | ▼ −4.70% | ▼ −8.21% | $5.07 (−17.83%) |
Jun 16, 2026 18w ago | 8-K | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.07 (+40.42%) |
Jun 16, 2026 18w ago | Press Release | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.07 (+40.42%) |
Jun 11, 2026 19w ago | Institutional Cluster | $14.69 $9.09 | ▼ −38.12% | ▼ −38.55% | $5.07 (−65.49%) |
May 12, 2026 23w ago | Press Release | $18.94 $16.69 | ▼ −11.88% | ▼ −10.72% | $5.07 (−73.23%) |
May 6, 2026 24w ago | Press Release | $16.65 $18.94 | ▲ +13.75% | ▲ +12.25% | $5.07 (−69.55%) |
Apr 16, 2026 27w ago | 8-K | $20.61 $18.70 | ▼ −9.27% | ▼ −9.82% | $5.07 (−75.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers